Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies

Fertility and Sterility

Volumn 84, Issue 1, 2005, Pages 108-117

  Wilcox, John ^a   Potter, Daniel ^b   Moore, Marva ^c   Ferrande, Lee ^c   Kelly, Eduardo ^d  

^a Huntington Reproductive Center   (United States)

^b Huntington Reproductive Center   (United States)

^c Reproductive Health Clinical Development Unit   (United States)

^d EMD SERONO INC   (United States)

Author keywords

Antagonist; Assisted reproductive technology; Cetrorelix acetate; Follitropin alfa; Ganirelix acetate; Inhibition of premature LH surge; Oral contraceptives programming

Indexed keywords

CETRORELIX; CONTRACEPTIVE AGENT; GANIRELIX; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT CHORIONIC GONADOTROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; HEALTH CENTER; HORMONE ACTION; HORMONE INHIBITION; HUMAN; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; OVARY FOLLICLE ATRESIA; PATIENT; PREGNANCY; PREGNANCY RATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; UNITED STATES;

ADULT; ANALYSIS OF VARIANCE; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; LUTEINIZING HORMONE; PREGNANCY; PREGNANCY RATE; PROSPECTIVE STUDIES; REPRODUCTIVE TECHNIQUES, ASSISTED;

EID: 22244433919     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2005.03.016     Document Type: Article

References (28)

1. R. Fleming, J.R.T. Coutts Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression Fertil Steril 45 1986 226 230
2. J.D. Stanger, J.L. Yovich Reduced in vitro fertilisation of human oocyte from patients with raised basal LH levels during the follicular phase Br J Obstet Gynaecol 92 1985 385 393
3. K. Droesch, S. Simonetti, S.J. Muasher, H.C. Liu, R.G. Brzyski, Z. Rosenwaks Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilization Fertil Steril 51 1989 292 297
4. J.M. Cummins, J.M. Yovich, W.R. Edirisinghe, J.L. Yovich Pituitary down-regulation using leuprolide for the intensive ovulation management of poor prognosis patients having in vitro fertilization (IVF)-related treatments J IVF ET 6 1989 345 352
5. E. Loumaye The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer Hum Reprod 5 1990 357 376
6. J. Smitz, R. Ron-El, B.C. Tarlatzis The use of gonadotrophin releasing hormone agonists for in vitro fertilization and other assisted procreation techniques experience from three centres Hum Reprod 7 1992 49 66
7. F. Olivennes, J.S. Cunha-Filho, R. Fanchin, P. Bouchard, R. Frydman The use of GnRH antagonists in ovarian stimulation Hum Reprod Update 8 2002 279 290
8. F. Olivennes, R. Fanchin, P. Bouchard, J. Taieb, J. Selva, D. De Ziegler The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program Fertil Steril 62 1994 468 476
9. F. Olivennes, R. Fanchin, P.H. Bouchard, J. Taïeb, J. Selva, R. Frydman Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles a pilot study Hum Reprod 10 1995 1382 1386
10. F. Olivennes, S. Alvarez, P. Bouchard, R. Fanchin, J. Salat-Baroux, R. Frydman The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer a dose finding study of 3 versus 2 mg Hum Reprod 13 1998 2411 2414
11. K. Diedrich, C. Diedrich, E. Santos, C. Zoll, S. Al-Hasani, T. Reissmann Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation Hum Reprod 9 1994 788 791
12. R. Felberbaum, T. Reissmann, W. Kupker, S. Al-Hasani, O. Bauer, T. Schill Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist cetrorelix at different dosages J Assist Reprod Genet 13 1996 216 221
13. C. Albano, H. Riethmuller-Winzen, J. Smitz, A. Van Steirteghem, M. Camus, P. Devroey Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation Fertil Steril 67 1997 917 922
14. F. Olivennes, J. Belaisch-Allart, J.-C. Emperaire, H. Dechaud, S. Alvarez, L. Moreau Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin) Fertil Steril 73 2000 314 320
15. C. Albano, R.E. Felberbaum, J. Smitz, H. Riethmüller-Winzen, J. Engel, K. Diedrich Ovarian stimulation with HMG results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin Hum Reprod 15 2000 526 531
16. R. Roulier Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment Reprod Biomed Online 7 2003 185 189
17. M. Ludwig, A. Katalinic, C. Banz, A.K. Schröder, M. Löning, J.M. Weiss Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF results of a prospective, randomized study Hum Reprod 17 2002 2842 2845
18. F. Olivennes, K. Diedrich, R. Frydman, R.E. Felderbaum, C.M. Howles Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges report of two large multicentre, multinational, phase IIIb clinical experiences Reprod Biomed Online 6 2003 432 438
19. The Ganirelix Dose Finding Group A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon) Hum Reprod 13 1998 3023 3031
20. G. Borm, B. Mannaerts The European Orgalutran Study Group Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient results of a controlled, randomized, multicentre trial Hum Reprod 15 2000 1490 1498
21. M. Fluker, J. Grifo, A. Leader, M. Levy, D. Meldrum, S.J. Muasher Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation Fertil Steril 75 2001 38 45
22. The European and Middle East Orgalutran Study Group Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin undergoing ovarian stimulation Hum Reprod 16 2001 644 651
23. M.H. Mochtar The Dutch Ganirelix Study Group The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI Hum Reprod 19 2004 1713 1718
24. A. Obruca, F. Fischl, J. Huber Programming oocyte retrieval using oral contraceptive pre-treatment prior to ovarian hyperstimulation with a GnRH antagonist (Cetrotide) protocol Hum Reprod 16 Suppl 1 2001 89
25. M.V. Sauer, M.H. Thornton, W. Schoolcraft, G.N. Frishman Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction Reprod Biomed Online 9 2004 487 493
26. E. Bosch, E. Escudero, J. Crespo, C. Simon, J. Remohi, A. Pellicer Follicular asynchrony in ovarian stimulation with GnRH antagonists [Abstract Book 1] Hum Reprod 17 2002 153
27. G. Griesinger, R.E. Felberbaum, A. Schultze-Mosgau, K. Diedrich Gonadotropin-releasing hormone antagonists for assisted reproductive techniques are there clinical differences between agents? Drugs 64 2004 563 575
28. S. Pang, B. Kaplan, V. Karande, L.M. Westphal, R. Scott, C. Givens Administration of recombinant human FSH (solution in cartridge) with a pen device in women undergoing ovarian stimulation Reprod Biomed Online 7 2003 319 325